ClinicalTrials.gg
CompletedNCT02052778Updated Mar 27, 2025Results posted

A Study of TAS-120 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of Futibatinib in Cholangiocarcinoma, Urothelial Cancer and Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, sponsored by Taiho Oncology, Inc.. Completed at 58 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
407
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 109 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
17th of 279
407 · median 44
Started
2014
with 17 others
Phase 1/2
42 of 328
12 open now
Registered
58th of 328
by date
Lead sponsor
5 of 328
Taiho Oncology, Inc.

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 17th largest by enrollment of the 279 interventional ones that give a count, is one of 18 that started in 2014, is one of 42 in phase 1/2, and was the 58th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, nonrandomized, Phase 1/2 study for the fibroblast growth factor receptor (FGFR) inhibitor futibatinib (TAS-120). The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, and anti-tumor activity of futibatinib in patients with advanced solid tumors with and without genomic FGF/FGFR abnormalities. The study will be conducted in 3 parts:

  1. Dose escalation portion to determine the -Maximum Tolerated Dose and/ or Recommended Phase 2 Dose of futibatinib.
  2. Phase 1 expansion portion to further evaluate the safety and efficacy of futibatinib in patients with tumors harboring FGF/FGFR aberrations, including patients with cholangiocarcinoma (CCA), primary central nervous system tumors, urothelial carcinoma, breast cancer, gastric cancer.
  3. Phase 2 study portion to confirm objective response rate of futibatinib in intrahepatic CCA patients with tumors harboring FGFR2 gene rearrangements (incl fusions).
03

Conditions studied

  • Cholangiocarcinoma
  • Urothelial Cancer
  • Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors
  • Primary CNS Tumors
  • Breast Cancer
  • Gastric Cancer

Keywords

  • FGF
  • FGFR
  • Futibatinib
  • TAS-120
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written
  2. Age ≥ 18 years of age
  3. Has or cytologically confirmed, locally advanced or cancer
  4. The following specific criteria for each study portion

    Phase 1 (Dose Escalation):

    • Patients with any type of solid tumor
    • Disease progression following standard therapies or intolerant to prior standard therapies

    Phase 1 (Dose Expansion)

    • Have at least one FGF/FGFR aberration
    • Disease progression following standard therapies or were intolerant to prior standard therapies (including prior FGFR inhibitors).
    • Have as defined by (RECIST) guidelines (version 1.1, 2009) for advanced solid tumors or Response Assessment in Neuro-Oncology criteria (2010) for brain tumors.
    • Patients with any of the following tumor types

      • Patients with intrahepatic or extrahepatic CCA harboring FGFR2 gene fusions or other FGFR2 aberrations
      • Patients with primary CNS tumors
      • Patients with advanced urothelial carcinoma with FGFR3 fusions or FGFR3 activating mutations
      • Patients with breast cancer or gastric cancer
      • Patients with other solid tumor types harboring FGFR gene fusions or activating mutations
      • Patients with solid tumor types and other FGF/FGFR alterations not listed above

    Phase 2

    • Patients with iCCA and FGFR2 gene rearrangements (incl fusions)
    • Have been treated with at least one prior systemic gemcitabine and platinum-based chemotherapy
    • Must have documentation of radiographic progression of disease
    • No prior FGFR inhibitor
    • Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1, 2009)
  5. (ECOG) performance status 0 or 1
  6. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. History and/or current evidence of non-tumor related alteration of calcium-phosphorus homeostasis.
  2. History and/or current evidence of clinically significant ectopic mineralization/calcification.
  3. History and/or current evidence of clinically significant retinal disorder
  4. A serious illness or medical condition(s)
  5. Pregnant or breast-feeding female
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
407 participants (actual)

Study arms

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 8 mg

    Participants with or without fibroblast growth factor \[FGF\]/fibroblast growth factor receptor \[FGFR\] gene abnormalities received orally TAS-120 8 milligrams (mg) orally every other day (QOD; Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 16 mg

    Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 16 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 24 mg

    Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 24 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 36 mg

    Participants with or without FGF/FGFR gene abnormalities received orally TAS-120 36 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 56 mg

    Participants with FGF/FGFR gene abnormalities received orally TAS-120 56 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 80 mg

    Participants with FGF/FGFR gene abnormalities received orally TAS-120 80 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 120 mg

    Participants with FGF/FGFR gene abnormalities received orally TAS-120 120 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 160 mg

    Participants with FGF/FGFR gene abnormalities received orally TAS-120 160 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QOD Dosing: 200 mg

    Participants with FGF/FGFR gene abnormalities received orally TAS-120 200 mg orally QOD (Monday, Wednesday and Friday of each week) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QD Dosing: 4 mg

    Participants with or without FGF/FGFR gene abnormalities received a dose between 4 mg orally once daily (QD) in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QD Dosing: 8 mg

    Participants with or without FGF/FGFR gene abnormalities received a dose between 8 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QD Dosing: 16 mg

    Participants with or without FGF/FGFR gene abnormalities received a dose between 16 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QD Dosing: 20 mg

    Participants with or without FGF/FGFR gene abnormalities received a dose between 20 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Escalation: QD Dosing: 24 mg

    Participants with or without FGF/FGFR gene abnormalities received a dose between 24 mg orally QD in a 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Expansion Cohort 1

    Participants with intra-hepatic or extrahepatic cholangiocarcinoma (iCCA or eCCA) harboring FGFR2 gene fusions or rearrangements and who were treated or not treated with prior FGFR inhibitors received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Expansion: Cohort 2

    Participants with primary central nervous system (CNS) tumors harboring FGFR gene fusions or FGFR1 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Expansion: Cohort 3

    Participants with advanced urothelial carcinoma harboring FGFR3 gene fusions or FGFR3 activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Expansion: Cohort 4

    Participants with breast or gastric cancer with harboring FGFR2 amplification received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1:Dose Expansion: Cohort 5

    Participants with tumor types harboring FGFR gene fusions or activating mutations received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Expansion: Cohort 6

    Participants who were not included in Cohorts 1 to 5 received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Expansion: Sub-cohort 1

    Participants with iCCA who were enrolled prior to the confirmation of the recommended Phase 2 dose (RP2D) received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 1: Dose Expansion: Sub-cohort 2

    Participants with other tumor types who were enrolled prior to the confirmation of the RP2D received TAS-120 16 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

  • Experimental
    Phase 2

    Participants with iCCA with tumors harboring FGFR2 gene rearrangements received TAS-120 20 mg tablets orally QD in each of 21-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent or death.

    Drug: Futibatinib

Interventions

  • oral once daily dosing, 21-day cycle

    Also known as: TAS-120

06

What researchers measure

Primary outcomes

  1. Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD)

    MTD:Highest dose level at which \<33% of participants experience dose-limiting toxicity (DLT) during Cycle1. DLT: \>=Grade(G)3: - nonhematologic toxicity, - nausea/vomiting lasting \>48hrs(uncontrolled by aggressive antiemetic), - diarrhea lasting \>48hrs (unresponsive to antidiarrheal drug); G4 neutropenia lasting \>7days; Febrile neutropenia (ANC\<1000/mm\^3 with body temperature=\>38.3°C/sustained temperature \>=38°C for \>1hr; Thrombocytopenia G4/G3 with bleeding, required blood transfusion; Corneal disorder worsened by 1 grade or more; Increased phosphorus: \>=9mg/dL or \>=7mg/dL lasting for \>=7days or phosphate lowering therapy\[PLT\] for 7days); Creatinine increase (\>1.5×upper limit of normal \[ULN\]) lasting for \>=7 days associated with serum phosphorus \>5.5 mg/dL(PLT=7days)/calcium×phosphorus \>55 mg/dL(PLT=7days); Hypercalcemia G2 for \>7days or G3; Ectopic de novo calcification in soft tissues; \>G2 DLT: prevented Cycle 1 completion, inability to start Cycle 2 within 2 weeks of schedule.

    Time frame: Cycle 1 (21-day cycle)

  2. Phase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120

    RP2D was MTD or less. MTD: Highest dose level at which \<33% of participants experience DLT) during Cycle1. DLT: \>=Grade(G)3: - nonhematologic toxicity, - nausea/vomiting lasting \>48hrs(uncontrolled by aggressive antiemetic), - diarrhea lasting \>48hrs (unresponsive to antidiarrheal drug); G4 neutropenia lasting \>7days; Febrile neutropenia (ANC\<1000/mm\^3 with body temperature=\>38.3°C/sustained temperature \>=38°C for \>1hr; Thrombocytopenia G4/G3 with bleeding, required blood transfusion; Corneal disorder worsened by 1 grade or more; Increased phosphorus: \>=9mg/dL or \>=7mg/dL lasting for \>=7days or phosphate lowering therapy\[PLT\] for 7days); Creatinine increase (\>1.5×upper limit of normal \[ULN\]) lasting for \>=7 days associated with serum phosphorus \>5.5 mg/dL(PLT=7days)/calcium×phosphorus \>55 mg/dL(PLT=7days); Hypercalcemia G2 for \>7days or G3; Ectopic de novo calcification in soft tissues; \>G2 DLT: prevented Cycle 1 completion, inability to start Cycle 2 within 2 weeks of schedule.

    Time frame: Cycle 1 (21-day cycle)

  3. Phase 1: Dose Expansion: Percentage of Participants With Objective Response

    Objective response was defined as proportion of participants who had achieved best overall response of partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \<10 millimeters (mm) and PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions. For Cohorts 1 to 6: Objective response was based on Independent Review Committee (IRC) and for pooled Sub-cohort: Objective response was based on investigator review.

    Time frame: Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohorts

  4. Phase 2: Percentage of Participants With Objective Response

    Objective response was defined as proportion of participants who had achieved best overall response of PR or CR per RECIST v1.1. CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \<10 mm and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. The Phase 2 evaluation of objective response was based on central independent CT/MRI image assessment.

    Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)

Secondary outcomes

  1. Phase 1: Dose Expansion: Duration of Response (DOR)

    A DOR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy. For Cohorts 1 to 6: DOR was based on IRC and for Group 3, 4, 5, 6 and for pooled Sub-cohort: DOR was based on investigator review.

    Time frame: Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohorts

  2. Phase 2: Duration of Response (DOR)

    A DOR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy. Kaplan-Meier method was used for the analysis.

    Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)

  3. Phase 1: Dose Expansion: Disease Control Rate (DCR)

    A DCR was defined as the proportion of participants with objective evidence of CR, PR, or stable disease (SD), except that there was no requirement for a confirmation of an SD, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. For Cohorts 1 to 6: DCR was based on IRC and for pooled Sub-cohort: DCR was based on investigator review.

    Time frame: Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohort

  4. Phase 2: Disease Control Rate (DCR)

    A DCR was defined as the proportion of participants with objective evidence of CR, PR, or SD, except that there was no requirement for a confirmation of an SD response, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. DCR was based on IRC.

    Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)

  5. Phase 1: Dose Expansion: Progression-free Survival (PFS)

    A PFS was defined as the time (in months) from the day of the first dose to the date of first documented disease progression or death (due to any cause), whichever occurred first. Participants who died without a reported disease progression were considered to have progressed on the date of their death, participants who did not progress or die were censored on the date of their last tumor assessment, participants who had no on-study assessments and did not die were censored on the first dosing date, and participants who started any subsequent anti-cancer therapy without a prior reported progression were censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. PFS assessment per protocol was by IRC assessment for Cohorts 1 to 6 and for pooled Sub-cohort: PFS was based on investigator review.

    Time frame: up to approximately 27.5 months (through cut-off date 30-Jun-2019)

  6. Phase 2: Progression-free Survival (PFS)

    A PFS was defined as the time (in months) from the day of the first dose to the date of first objectively documented disease progression or death (any cause), whichever occurred first. Participants who had died without a reported disease progression were considered to have progressed on the date of their death, participants who did not progress or die were censored on the date of their last tumor assessment, participants who had no on-study assessments and did not die were censored on the first dosing date, and participants who started any subsequent anti-cancer therapy without a prior reported progression were censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. PFS was analyzed as using Kaplan-Meier estimate.

    Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)

  7. Phase 1: Dose Expansion: Overall Survival (OS)

    An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.

    Time frame: up to approximately 27.5 months (through cut-off date 30-Jun-2019)

  8. Phase 2: Overall Survival (OS)

    An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.

    Time frame: Up to approximately 37.5 months (through cut-off date 29-May-2021)

  9. Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Scores at Specified Visits

    EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

    Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])

  10. Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Self-care Scores at Specified Visits

    EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

    Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])

  11. Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Usual Activities Scores at Specified Visits

    EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

    Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])

  12. Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Pain/Discomfort Scores at Specified Visits

    EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

    Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])

  13. Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Anxiety/Depression Scores at Specified Visits

    EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

    Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])

  14. Phase 2: Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Specified Visits

    EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. A vertical VAS allows the participants to indicate their health state that day, and ranged from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.

    Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])

  15. Phase 2:Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score at Specified Timepoints

    EORTC QLQ-C30 is a cancer-specific instrument that contains 30 questions for evaluation of new chemotherapy \& assessment of participant reported outcome. EORTC QLQ-C30 included global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\[{Q29+Q30}/2\]-1)/6\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant.

    Time frame: Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])

  16. Phase 1: Dose Expansion: Number of Participants With Any Adverse Events (AEs) and Any Serious AEs (SAEs)

    An AE was defined as any untoward medical condition that occurred in a participant from the time the informed consent form (ICF) was signed and does not necessarily had a causal relationship with the use of the product. An SAE was an AE that falls into one or more of the following categories: a. resulted in death, b. was life threatening, c. required inpatient hospitalization or prolongation of existing hospitalization, d. resulted in persistent or significant disability or incapacity, e. was a congenital anomaly/birth defect, f. other important medical event.

    Time frame: From the first dose up to approximately 50.5 months (through cut-off date 29-May-2021)

  17. Phase 2: Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)

    An AE was defined as any untoward medical condition that occurs in a participant from the time the informed consent form (ICF) was signed and does not necessarily had a causal relationship with the use of the product. An SAE was an AE that falls into one or more of the following categories: a. resulted in death, b. was life threatening, c. required inpatient hospitalization or prolongation of existing hospitalization, d. resulted in persistent or significant disability or incapacity, e. was a congenital anomaly/birth defect, f. other important medical event.

    Time frame: From the first dose up to approximately 37.5 months (through cut-off date 29-May-2021)

07

Results

Posted Mar 20, 2024

Participant flow

Study had Phase 1 and 2. Phase 1 included Dose escalation: 86 participants were enrolled \& treated and Dose Expansion: 284 participants were screened, of which 201 were enrolled; 197 were treated \& 4 were not treated. Phase 2: 120 participants signed informed consent, of which 17 were screen failures \& thus 103 were treated. In Participant Flow, Baseline Characteristics \& Adverse events, combined arm presentation of QOD \& QD dosing was made for Phase 1 Dose Escalation as pre-planned in protocol.

Dose Escalation(Approximately 60 Months)
Participant flow — Dose Escalation(Approximately 60 Months)
MilestonePhase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1:Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 1Phase 1: Dose Expansion: Sub-cohort 2Phase 2
Started6333354874514714000000000
Completed00000000000000000000000
Not completed6333354874514714000000000
Withdrew: Radiographic progression422123065451147000000000
Withdrew: Clinical disease progression21121132100223000000000
Withdrew: Adverse event00000000000001000000000
Withdrew: Death00000010000100000000000
Withdrew: Withdrawal by participant00000000100003000000000
Withdrew: Investigator decision00000100000010000000000
Dose Expansion (Approximately 59 Months)
Participant flow — Dose Expansion (Approximately 59 Months)
MilestonePhase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1:Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 1Phase 1: Dose Expansion: Sub-cohort 2Phase 2
Started000000000000005835161325271980
Treated000000000000005734151324271980
Completed00000000000000000000000
Not completed000000000000005835161325271980
Withdrew: Radiographic progression000000000000003823121117211460
Withdrew: Clinical disease progression00000000000000630234510
Withdrew: Adverse event00000000000000513031000
Withdrew: Withdrawal by subject00000000000000230000000
Withdrew: Investigator decision00000000000000530001000
Withdrew: Other00000000000000110010010
Withdrew: Untreated00000000000000111010000
Phase 2 (Approximately 63 Months)
Participant flow — Phase 2 (Approximately 63 Months)
MilestonePhase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1:Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 1Phase 1: Dose Expansion: Sub-cohort 2Phase 2
Started0000000000000000000000120
Treated0000000000000000000000103
Completed00000000000000000000000
Not completed0000000000000000000000120
Withdrew: Adverse event00000000000000000000007
Withdrew: Radiologic progression000000000000000000000078
Withdrew: Clinical disease progression00000000000000000000006
Withdrew: Withdrawal by participant00000000000000000000002
Withdrew: Investigator decision00000000000000000000003
Withdrew: Other00000000000000000000007
Withdrew: Untreated000000000000000000000017

Outcome measures

PrimaryPhase 1: Dose Escalation-Maximum Tolerated Dose (MTD)

MTD:Highest dose level at which \<33% of participants experience dose-limiting toxicity (DLT) during Cycle1. DLT: \>=Grade(G)3: - nonhematologic toxicity, - nausea/vomiting lasting \>48hrs(uncontrolled by aggressive antiemetic), - diarrhea lasting \>48hrs (unresponsive to antidiarrheal drug); G4 neutropenia lasting \>7days; Febrile neutropenia (ANC\<1000/mm\^3 with body temperature=\>38.3°C/sustained temperature \>=38°C for \>1hr; Thrombocytopenia G4/G3 with bleeding, required blood transfusion; Corneal disorder worsened by 1 grade or more; Increased phosphorus: \>=9mg/dL or \>=7mg/dL lasting for \>=7days or phosphate lowering therapy\[PLT\] for 7days); Creatinine increase (\>1.5×upper limit of normal \[ULN\]) lasting for \>=7 days associated with serum phosphorus \>5.5 mg/dL(PLT=7days)/calcium×phosphorus \>55 mg/dL(PLT=7days); Hypercalcemia G2 for \>7days or G3; Ectopic de novo calcification in soft tissues; \>G2 DLT: prevented Cycle 1 completion, inability to start Cycle 2 within 2 weeks of schedule.

Time frame:
Cycle 1 (21-day cycle)
Reported as:
Number · Milligrams
Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD)
MilligramsPhase 1: Dose Escalation: QOD DosingPhase 1: Dose Escalation: QD Dosing
Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD)NA20
PrimaryPhase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120

RP2D was MTD or less. MTD: Highest dose level at which \<33% of participants experience DLT) during Cycle1. DLT: \>=Grade(G)3: - nonhematologic toxicity, - nausea/vomiting lasting \>48hrs(uncontrolled by aggressive antiemetic), - diarrhea lasting \>48hrs (unresponsive to antidiarrheal drug); G4 neutropenia lasting \>7days; Febrile neutropenia (ANC\<1000/mm\^3 with body temperature=\>38.3°C/sustained temperature \>=38°C for \>1hr; Thrombocytopenia G4/G3 with bleeding, required blood transfusion; Corneal disorder worsened by 1 grade or more; Increased phosphorus: \>=9mg/dL or \>=7mg/dL lasting for \>=7days or phosphate lowering therapy\[PLT\] for 7days); Creatinine increase (\>1.5×upper limit of normal \[ULN\]) lasting for \>=7 days associated with serum phosphorus \>5.5 mg/dL(PLT=7days)/calcium×phosphorus \>55 mg/dL(PLT=7days); Hypercalcemia G2 for \>7days or G3; Ectopic de novo calcification in soft tissues; \>G2 DLT: prevented Cycle 1 completion, inability to start Cycle 2 within 2 weeks of schedule.

Time frame:
Cycle 1 (21-day cycle)
Reported as:
Number · Milligrams
Phase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120
MilligramsPhase 1: Dose Escalation: QOD DosingPhase 1: Dose Escalation: QD Dosing
Phase 1: Dose Escalation-Recommended Phase 2 Dose (RP2D) of TAS-120NA20
PrimaryPhase 1: Dose Expansion: Percentage of Participants With Objective Response

Objective response was defined as proportion of participants who had achieved best overall response of partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \<10 millimeters (mm) and PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions. For Cohorts 1 to 6: Objective response was based on Independent Review Committee (IRC) and for pooled Sub-cohort: Objective response was based on investigator review.

Time frame:
Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohorts
Reported as:
Number · Percentage of participants
Phase 1: Dose Expansion: Percentage of Participants With Objective Response
Percentage of participantsPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Pooled Sub-cohort
Phase 1: Dose Expansion: Percentage of Participants With Objective Response15.8 (7.5 to 27.9)8.8 (1.9 to 23.7)13.3 (1.7 to 40.5)0 (0.0 to 24.7)12.5 (2.7 to 32.4)0 (0.0 to 12.8)33.3 (16.5 to 54.0)
PrimaryPhase 2: Percentage of Participants With Objective Response

Objective response was defined as proportion of participants who had achieved best overall response of PR or CR per RECIST v1.1. CR was defined as a disappearance of all target lesions. Any pathological lymph nodes (target or non-target) must had reduction in short axis to \<10 mm and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. The Phase 2 evaluation of objective response was based on central independent CT/MRI image assessment.

Time frame:
Up to approximately 37.5 months (through cut-off date 29-May-2021)
Reported as:
Number · Percentage of participants
Phase 2: Percentage of Participants With Objective Response
Percentage of participantsPhase 2
Phase 2: Percentage of Participants With Objective Response41.7 (32.1 to 51.9)
SecondaryPhase 1: Dose Expansion: Duration of Response (DOR)

A DOR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy. For Cohorts 1 to 6: DOR was based on IRC and for Group 3, 4, 5, 6 and for pooled Sub-cohort: DOR was based on investigator review.

Time frame:
Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohorts
Reported as:
Median · months
Phase 1: Dose Expansion: Duration of Response (DOR)
monthsPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Pooled Sub-cohort
Phase 1: Dose Expansion: Duration of Response (DOR)6.18 (2.8 to 10.6)3.52 (2.8 to 4.3)2.45 (1.4 to 3.4)—2.79 (2.0 to 4.1)—8.77 (3.5 to 20.8)
SecondaryPhase 2: Duration of Response (DOR)

A DOR was defined as the time (in months) from the first documentation of response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. Participants who started subsequent anticancer therapy without a prior reported progression were censored at the last tumor assessments prior to initiation of the subsequent anticancer therapy. Kaplan-Meier method was used for the analysis.

Time frame:
Up to approximately 37.5 months (through cut-off date 29-May-2021)
Reported as:
Median · months
Phase 2: Duration of Response (DOR)
monthsPhase 2
Phase 2: Duration of Response (DOR)8.31 (2.1 to 24.8)
SecondaryPhase 1: Dose Expansion: Disease Control Rate (DCR)

A DCR was defined as the proportion of participants with objective evidence of CR, PR, or stable disease (SD), except that there was no requirement for a confirmation of an SD, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. For Cohorts 1 to 6: DCR was based on IRC and for pooled Sub-cohort: DCR was based on investigator review.

Time frame:
Up to approximately 50.5 months (through cut-off date 29-May-2021) for Cohorts 1 to 6; up to approximately 27.5 months (through cut-off date 30-Jun-2019) for pooled sub-cohort
Reported as:
Number · Percentage of participants
Phase 1: Dose Expansion: Disease Control Rate (DCR)
Percentage of participantsPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Pooled Sub-cohort
Phase 1: Dose Expansion: Disease Control Rate (DCR)66.7 (52.9 to 78.6)23.5 (10.7 to 41.2)33.3 (11.8 to 61.6)38.5 (13.9 to 68.4)54.2 (32.8 to 74.4)22.2 (8.6 to 42.3)66.7 (46.0 to 83.5)
SecondaryPhase 2: Disease Control Rate (DCR)

A DCR was defined as the proportion of participants with objective evidence of CR, PR, or SD, except that there was no requirement for a confirmation of an SD response, if it is maintained for at least 6 weeks post treatment initiation. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes might had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of the target lesions, taking as a reference the Baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taken as a reference the smallest sum diameters while on study. DCR was based on IRC.

Time frame:
Up to approximately 37.5 months (through cut-off date 29-May-2021)
Reported as:
Number · Percentage of participants
Phase 2: Disease Control Rate (DCR)
Percentage of participantsPhase 2
Phase 2: Disease Control Rate (DCR)82.5 (73.8 to 89.3)
SecondaryPhase 1: Dose Expansion: Progression-free Survival (PFS)

A PFS was defined as the time (in months) from the day of the first dose to the date of first documented disease progression or death (due to any cause), whichever occurred first. Participants who died without a reported disease progression were considered to have progressed on the date of their death, participants who did not progress or die were censored on the date of their last tumor assessment, participants who had no on-study assessments and did not die were censored on the first dosing date, and participants who started any subsequent anti-cancer therapy without a prior reported progression were censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. PFS assessment per protocol was by IRC assessment for Cohorts 1 to 6 and for pooled Sub-cohort: PFS was based on investigator review.

Time frame:
up to approximately 27.5 months (through cut-off date 30-Jun-2019)
Reported as:
Median · months
Phase 1: Dose Expansion: Progression-free Survival (PFS)
monthsPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Pooled Sub-cohort
Phase 1: Dose Expansion: Progression-free Survival (PFS)4.1 (2.7 to 6.9)1.9 (1.3 to 4.9)1.8 (1.3 to 4.7)1.3 (0.9 to 4.1)3.5 (1.7 to 6.8)2.7 (1.4 to 2.7)6.9 (4.6 to 10.8)
SecondaryPhase 2: Progression-free Survival (PFS)

A PFS was defined as the time (in months) from the day of the first dose to the date of first objectively documented disease progression or death (any cause), whichever occurred first. Participants who had died without a reported disease progression were considered to have progressed on the date of their death, participants who did not progress or die were censored on the date of their last tumor assessment, participants who had no on-study assessments and did not die were censored on the first dosing date, and participants who started any subsequent anti-cancer therapy without a prior reported progression were censored at the last tumor assessment prior to initiation of the subsequent anti-cancer therapy. PFS was analyzed as using Kaplan-Meier estimate.

Time frame:
Up to approximately 37.5 months (through cut-off date 29-May-2021)
Reported as:
Median · months
Phase 2: Progression-free Survival (PFS)
monthsPhase 2
Phase 2: Progression-free Survival (PFS)8.9 (6.7 to 11.0)
SecondaryPhase 1: Dose Expansion: Overall Survival (OS)

An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.

Time frame:
up to approximately 27.5 months (through cut-off date 30-Jun-2019)
Reported as:
Median · months
Phase 1: Dose Expansion: Overall Survival (OS)
monthsPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Pooled Sub-cohort
Phase 1: Dose Expansion: Overall Survival (OS)11.4 (8.1 to 15.1)11.8 (5.5 to NA)8.6 (2.1 to NA)5.8 (4.6 to NA)10.5 (6.7 to NA)7.2 (5.6 to NA)NA (12.2 to NA)
SecondaryPhase 2: Overall Survival (OS)

An OS was defined as the time (in months) from the date of the first dose to the death date. In the absence of death confirmation or for participants alive as of the OS cut-off date, survival time was censored at the date of last study follow-up, or the cut-off date, whichever was earlier.

Time frame:
Up to approximately 37.5 months (through cut-off date 29-May-2021)
Reported as:
Median · months
Phase 2: Overall Survival (OS)
monthsPhase 2
Phase 2: Overall Survival (OS)20.0 (16.4 to 24.6)
SecondaryPhase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Scores at Specified Visits

EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

Time frame:
Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Reported as:
Count of participants · Participants
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Mobility Scores at Specified Visits
ParticipantsPhase 2
Baseline — No Problem72
Baseline — Some Problem18
Baseline — Extreme Problem0
Cycle 2 — No Problem60
Cycle 2 — Some Problem20
Cycle 2 — Extreme Problem1
Cycle 4 — No Problem60
Cycle 4 — Some Problem18
Cycle 4 — Extreme Problem0
Cycle 7 — No Problem51
Cycle 7 — Some Problem14
Cycle 7 — Extreme Problem0
Cycle 10 — No Problem42
Cycle 10 — Some Problem16
Cycle 10 — Extreme Problem0
Cycle 13 — No Problem32
Cycle 13 — Some Problem15
Cycle 13 — Extreme Problem0
Cycle 16 — No Problem23
Cycle 16 — Some Problem12
Cycle 16 — Extreme Problem0
Cycle 19 — No Problem16
Cycle 19 — Some Problem12
Cycle 19 — Extreme Problem0
Cycle 22 — No Problem9
Cycle 22 — Some Problem12
Cycle 22 — Extreme Problem0
Cycle 25 — No Problem9
Cycle 25 — Some Problem2
Cycle 25 — Extreme Problem1
Cycle 28 — No Problem6
Cycle 28 — Some Problem2
Cycle 28 — Extreme Problem0
Cycle 31 — No Problem3
Cycle 31 — Some Problem0
Cycle 31 — Extreme Problem0
Cycle 34 — No Problem3
Cycle 34 — Some Problem0
Cycle 34 — Extreme Problem0
Cycle 37 — No Problem2
Cycle 37 — Some Problem1
Cycle 37 — Extreme Problem0
Cycle 40 — No Problem0
Cycle 40 — Some Problem1
Cycle 40 — Extreme Problem0
End of Treatment — No Problem23
End of Treatment — Some Problem20
End of Treatment — Extreme Problem1
SecondaryPhase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Self-care Scores at Specified Visits

EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

Time frame:
Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Reported as:
Count of participants · Participants
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Self-care Scores at Specified Visits
ParticipantsPhase 2
Baseline — No Problem82
Baseline — Some Problem8
Baseline — Extreme Problem0
Cycle 2 — No Problem75
Cycle 2 — Some Problem6
Cycle 2 — Extreme Problem0
Cycle 4 — No Problem70
Cycle 4 — Some Problem7
Cycle 4 — Extreme Problem1
Cycle 7 — No Problem58
Cycle 7 — Some Problem6
Cycle 7 — Extreme Problem1
Cycle 10 — No Problem52
Cycle 10 — Some Problem5
Cycle 10 — Extreme Problem1
Cycle 13 — No Problem41
Cycle 13 — Some Problem6
Cycle 13 — Extreme Problem0
Cycle 16 — No Problem30
Cycle 16 — Some Problem4
Cycle 16 — Extreme Problem1
Cycle 19 — No Problem22
Cycle 19 — Some Problem6
Cycle 19 — Extreme Problem0
Cycle 22 — No Problem18
Cycle 22 — Some Problem3
Cycle 22 — Extreme Problem0
Cycle 25 — No Problem9
Cycle 25 — Some Problem3
Cycle 25 — Extreme Problem0
Cycle 28 — No Problem8
Cycle 28 — Some Problem0
Cycle 28 — Extreme Problem0
Cycle 31 — No Problem3
Cycle 31 — Some Problem0
Cycle 31 — Extreme Problem0
Cycle 34 — No Problem3
Cycle 34 — Some Problem0
Cycle 34 — Extreme Problem0
Cycle 37 — No Problem2
Cycle 37 — Some Problem1
Cycle 37 — Extreme Problem0
Cycle 40 — No Problem1
Cycle 40 — Some Problem0
Cycle 40 — Extreme Problem0
End of Treatment — No Problem34
End of Treatment — Some Problem8
End of Treatment — Extreme Problem1
SecondaryPhase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Usual Activities Scores at Specified Visits

EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

Time frame:
Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Reported as:
Count of participants · Participants
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Usual Activities Scores at Specified Visits
ParticipantsPhase 2
Baseline — No Problem63
Baseline — Some Problem24
Baseline — Extreme Problem2
Cycle 2 — No Problem47
Cycle 2 — Some Problem32
Cycle 2 — Extreme Problem2
Cycle 4 — No Problem50
Cycle 4 — Some Problem27
Cycle 4 — Extreme Problem1
Cycle 7 — No Problem43
Cycle 7 — Some Problem20
Cycle 7 — Extreme Problem2
Cycle 10 — No Problem34
Cycle 10 — Some Problem23
Cycle 10 — Extreme Problem1
Cycle 13 — No Problem28
Cycle 13 — Some Problem19
Cycle 13 — Extreme Problem0
Cycle 16 — No Problem20
Cycle 16 — Some Problem14
Cycle 16 — Extreme Problem1
Cycle 19 — No Problem15
Cycle 19 — Some Problem12
Cycle 19 — Extreme Problem1
Cycle 22 — No Problem7
Cycle 22 — Some Problem14
Cycle 22 — Extreme Problem0
Cycle 25 — No Problem4
Cycle 25 — Some Problem7
Cycle 25 — Extreme Problem1
Cycle 28 — No Problem3
Cycle 28 — Some Problem5
Cycle 28 — Extreme Problem0
Cycle 31 — No Problem1
Cycle 31 — Some Problem2
Cycle 31 — Extreme Problem0
Cycle 34 — No Problem2
Cycle 34 — Some Problem1
Cycle 34 — Extreme Problem0
Cycle 37 — No Problem0
Cycle 37 — Some Problem3
Cycle 37 — Extreme Problem0
Cycle 40 — No Problem0
Cycle 40 — Some Problem1
Cycle 40 — Extreme Problem0
End of Treatment — No Problem16
End of Treatment — Some Problem25
End of Treatment — Extreme Problem3
SecondaryPhase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Pain/Discomfort Scores at Specified Visits

EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

Time frame:
Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Reported as:
Count of participants · Participants
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Pain/Discomfort Scores at Specified Visits
ParticipantsPhase 2
Baseline — No Problem42
Baseline — Some Problem47
Baseline — Extreme Problem1
Cycle 2 — No Problem45
Cycle 2 — Some Problem35
Cycle 2 — Extreme Problem1
Cycle 4 — No Problem40
Cycle 4 — Some Problem36
Cycle 4 — Extreme Problem2
Cycle 7 — No Problem36
Cycle 7 — Some Problem29
Cycle 7 — Extreme Problem1
Cycle 10 — No Problem30
Cycle 10 — Some Problem26
Cycle 10 — Extreme Problem2
Cycle 13 — No Problem23
Cycle 13 — Some Problem22
Cycle 13 — Extreme Problem2
Cycle 16 — No Problem13
Cycle 16 — Some Problem19
Cycle 16 — Extreme Problem3
Cycle 19 — No Problem13
Cycle 19 — Some Problem15
Cycle 19 — Extreme Problem0
Cycle 22 — No Problem6
Cycle 22 — Some Problem14
Cycle 22 — Extreme Problem1
Cycle 25 — No Problem3
Cycle 25 — Some Problem9
Cycle 25 — Extreme Problem0
Cycle 28 — No Problem2
Cycle 28 — Some Problem5
Cycle 28 — Extreme Problem1
Cycle 31 — No Problem2
Cycle 31 — Some Problem1
Cycle 31 — Extreme Problem0
Cycle 34 — No Problem3
Cycle 34 — Some Problem0
Cycle 34 — Extreme Problem0
Cycle 37 — No Problem2
Cycle 37 — Some Problem1
Cycle 37 — Extreme Problem0
Cycle 40 — No Problem0
Cycle 40 — Some Problem1
Cycle 40 — Extreme Problem0
End of Treatment — No Problem12
End of Treatment — Some Problem27
End of Treatment — Extreme Problem5
SecondaryPhase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Anxiety/Depression Scores at Specified Visits

EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension was rated on 3 levels of function: no problem, some problem and extreme problem. In this outcome measure, data were reported categorically as the number of participants who chose each category.

Time frame:
Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Reported as:
Count of participants · Participants
Phase 2: European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Questionnaire: Anxiety/Depression Scores at Specified Visits
ParticipantsPhase 2
Baseline — No Problem64
Baseline — Some Problem25
Baseline — Extreme Problem0
Cycle 2 — No Problem66
Cycle 2 — Some Problem15
Cycle 2 — Extreme Problem0
Cycle 4 — No Problem63
Cycle 4 — Some Problem14
Cycle 4 — Extreme Problem1
Cycle 7 — No Problem48
Cycle 7 — Some Problem15
Cycle 7 — Extreme Problem2
Cycle 10 — No Problem44
Cycle 10 — Some Problem12
Cycle 10 — Extreme Problem2
Cycle 13 — No Problem36
Cycle 13 — Some Problem11
Cycle 13 — Extreme Problem0
Cycle 16 — No Problem26
Cycle 16 — Some Problem8
Cycle 16 — Extreme Problem1
Cycle 19 — No Problem21
Cycle 19 — Some Problem6
Cycle 19 — Extreme Problem1
Cycle 22 — No Problem13
Cycle 22 — Some Problem8
Cycle 22 — Extreme Problem0
Cycle 25 — No Problem8
Cycle 25 — Some Problem4
Cycle 25 — Extreme Problem0
Cycle 28 — No Problem5
Cycle 28 — Some Problem3
Cycle 28 — Extreme Problem0
Cycle 31 — No Problem2
Cycle 31 — Some Problem1
Cycle 31 — Extreme Problem0
Cycle 34 — No Problem2
Cycle 34 — Some Problem1
Cycle 34 — Extreme Problem0
Cycle 37 — No Problem1
Cycle 37 — Some Problem2
Cycle 37 — Extreme Problem0
Cycle 40 — No Problem0
Cycle 40 — Some Problem1
Cycle 40 — Extreme Problem0
End of Treatment — No Problem22
End of Treatment — Some Problem19
End of Treatment — Extreme Problem3
SecondaryPhase 2: Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Specified Visits

EQ-5D-3L was a self-administered standardized questionnaire to assess health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. A vertical VAS allows the participants to indicate their health state that day, and ranged from 0 (worst imaginable) to 100 (best imaginable), with higher scores indicating better health state.

Time frame:
Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Reported as:
Mean · score on a scale
Phase 2: Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Specified Visits
score on a scalePhase 2
Baseline71.72 ± 20.307
Change at Cycle 2-0.73 ± 19.409
Change at Cycle 4-1.04 ± 23.984
Change at Cycle 7-1.82 ± 29.984
Change at Cycle 100.40 ± 30.428
Change at Cycle 134.76 ± 26.585
Change at Cycle 16-1.71 ± 34.417
Change at Cycle 191.76 ± 25.155
Change at Cycle 221.85 ± 31.707
Change at Cycle 25-0.82 ± 45.828
Change at Cycle 28-1.85 ± 40.912
Change at Cycle 3118.17 ± 17.280
Change at Cycle 3419.00 ± 19.313
Change at Cycle 3715.17 ± 21.624
Change at Cycle 4015.00
End of Treatment-8.89 ± 26.272
SecondaryPhase 2:Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score at Specified Timepoints

EORTC QLQ-C30 is a cancer-specific instrument that contains 30 questions for evaluation of new chemotherapy \& assessment of participant reported outcome. EORTC QLQ-C30 included global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale \& are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as (\[{Q29+Q30}/2\]-1)/6\*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant.

Time frame:
Baseline, Cycle 2, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40 and end of treatment (i.e., Cycle 43 [30 months])
Reported as:
Mean · score on scale
Phase 2:Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status Score at Specified Timepoints
score on scalePhase 2
Baseline70.1 ± 19.41
Change at Cycle 2-1.0 ± 22.02
Change at Cycle 40.4 ± 20.62
Change at Cycle 7-0.5 ± 21.64
Change at Cycle 101.9 ± 22.84
Change at Cycle 130.9 ± 21.49
Change at Cycle 162.5 ± 18.61
Change at Cycle 19-1.7 ± 17.31
Change at Cycle 22-8.3 ± 22.05
Change at Cycle 25-4.8 ± 21.44
Change at Cycle 28-6.3 ± 12.50
Change at Cycle 3141.7
Change at Cycle 3441.7
End of Treatment-7.5 ± 23.30
SecondaryPhase 1: Dose Expansion: Number of Participants With Any Adverse Events (AEs) and Any Serious AEs (SAEs)

An AE was defined as any untoward medical condition that occurred in a participant from the time the informed consent form (ICF) was signed and does not necessarily had a causal relationship with the use of the product. An SAE was an AE that falls into one or more of the following categories: a. resulted in death, b. was life threatening, c. required inpatient hospitalization or prolongation of existing hospitalization, d. resulted in persistent or significant disability or incapacity, e. was a congenital anomaly/birth defect, f. other important medical event.

Time frame:
From the first dose up to approximately 50.5 months (through cut-off date 29-May-2021)
Reported as:
Count of participants · Participants
Phase 1: Dose Expansion: Number of Participants With Any Adverse Events (AEs) and Any Serious AEs (SAEs)
ParticipantsPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 1Phase 1: Dose Expansion: Sub-cohort 2
AEs573415132326185
SAEs2713109131400
SecondaryPhase 2: Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)

An AE was defined as any untoward medical condition that occurs in a participant from the time the informed consent form (ICF) was signed and does not necessarily had a causal relationship with the use of the product. An SAE was an AE that falls into one or more of the following categories: a. resulted in death, b. was life threatening, c. required inpatient hospitalization or prolongation of existing hospitalization, d. resulted in persistent or significant disability or incapacity, e. was a congenital anomaly/birth defect, f. other important medical event.

Time frame:
From the first dose up to approximately 37.5 months (through cut-off date 29-May-2021)
Reported as:
Count of participants · Participants
Phase 2: Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs)
ParticipantsPhase 2
AEs103
SAEs42

Adverse events

Collected over From the first dose administration up to approximately up to 59.5 months for Phase 1 Dose escalation; up to 50.5 months for Phase 1 Dose expansion Cohorts and up to 37.5 months for Phase 2. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1: Dose Escalation: QOD Dosing: 8 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Phase 1: Dose Escalation: QOD Dosing: 16 mg0/3 (0%)0/3 (0%)3/3 (100%)
Phase 1: Dose Escalation: QOD Dosing: 24 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 1: Dose Escalation: QOD Dosing: 36 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 1: Dose Escalation: QOD Dosing: 56 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Phase 1: Dose Escalation: QOD Dosing: 80 mg0/5 (0%)2/5 (40%)5/5 (100%)
Phase 1: Dose Escalation: QOD Dosing: 120 mg1/4 (25%)4/4 (100%)4/4 (100%)
Phase 1: Dose Escalation: QOD Dosing: 160 mg0/8 (0%)7/8 (87.5%)8/8 (100%)
Phase 1: Dose Escalation: QOD Dosing: 200 mg2/7 (28.6%)4/7 (57.1%)7/7 (100%)
Phase 1: Dose Escalation: QD Dosing: 4 mg0/4 (0%)0/4 (0%)4/4 (100%)
Phase 1: Dose Escalation: QD Dosing: 8 mg0/5 (0%)1/5 (20%)5/5 (100%)
Phase 1: Dose Escalation: QD Dosing: 16 mg2/14 (14.3%)9/14 (64.3%)14/14 (100%)
Phase 1: Dose Escalation: QD Dosing: 20 mg1/7 (14.3%)3/7 (42.9%)7/7 (100%)
Phase 1: Dose Escalation: QD Dosing: 24 mg1/14 (7.1%)6/14 (42.9%)14/14 (100%)
Phase 1: Dose Expansion Cohort 140/57 (70.2%)27/57 (47.4%)57/57 (100%)
Phase 1: Dose Expansion: Cohort 222/34 (64.7%)13/34 (38.2%)34/34 (100%)
Phase 1: Dose Expansion: Cohort 312/15 (80%)10/15 (66.7%)15/15 (100%)
Phase 1: Dose Expansion: Cohort 411/13 (84.6%)9/13 (69.2%)13/13 (100%)
Phase 1: Dose Expansion: Cohort 515/24 (62.5%)13/24 (54.2%)23/24 (95.8%)
Phase 1: Dose Expansion: Cohort 617/27 (63%)14/27 (51.9%)26/27 (96.3%)
Phase 1: Dose Expansion: Sub-cohort 21/8 (12.5%)0/8 (0%)8/8 (100%)
Phase 1: Dose Expansion: Sub-cohort 19/19 (47.4%)0/19 (0%)19/19 (100%)
Phase 258/103 (56.3%)42/103 (40.8%)103/103 (100%)
Most frequent serious events
Showing 10 of 157
Most frequent serious events
EventPhase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 2Phase 1: Dose Expansion: Sub-cohort 1Phase 2
AnaemiaBlood and lymphatic system disorders0/60/31/30/30/30/50/40/80/70/40/50/140/70/141/570/340/150/130/241/270/80/191/103
PyrexiaGeneral disorders0/60/30/30/31/30/50/40/80/70/40/50/140/71/141/570/340/150/130/241/270/80/194/103
CellulitisInfections and infestations0/60/31/30/30/30/50/40/80/70/40/50/140/71/140/570/340/150/130/240/270/80/191/103
PneumoniaInfections and infestations0/60/30/31/30/31/50/41/80/70/40/50/141/70/140/570/340/150/130/241/270/80/191/103
HypercalcaemiaMetabolism and nutrition disorders0/60/30/31/30/30/51/40/80/70/40/50/140/70/141/570/340/150/130/240/270/80/191/103
Disease progressionGeneral disorders0/60/30/30/30/30/50/40/81/70/40/51/142/71/142/570/343/152/130/241/270/80/195/103
Abdominal painGastrointestinal disorders0/60/30/30/30/30/50/42/81/70/40/51/140/70/143/570/340/151/131/240/270/80/191/103
NauseaGastrointestinal disorders0/60/30/30/30/30/51/40/80/70/40/50/141/71/141/570/340/150/130/240/270/80/191/103
VomitingGastrointestinal disorders0/60/30/30/30/30/51/40/80/70/40/50/141/71/141/570/340/150/130/240/270/80/191/103
HemiparesisNervous system disorders0/60/30/30/30/30/51/40/80/70/40/50/140/70/140/572/340/150/130/240/270/80/190/103
Most frequent other events
Showing 10 of 336
Most frequent other events
EventPhase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 2Phase 1: Dose Expansion: Sub-cohort 1Phase 2
DiarrhoeaGastrointestinal disorders0/63/31/30/31/31/52/46/83/70/40/55/143/77/1417/5713/344/153/1311/2410/275/85/1937/103
HyperphosphataemiaMetabolism and nutrition disorders0/61/31/30/30/34/53/46/86/71/42/59/146/712/1448/5730/349/1512/1319/2421/275/817/1988/103
Dry mouthGastrointestinal disorders2/60/31/32/30/31/53/43/82/72/41/54/141/73/1413/574/343/151/133/247/270/87/1936/103
Abdominal pain upperGastrointestinal disorders0/61/30/32/30/30/50/40/80/71/40/51/141/70/144/572/340/150/130/243/270/83/198/103
AstheniaGeneral disorders1/62/30/31/31/31/50/42/81/71/41/54/141/72/147/577/342/150/134/246/271/81/194/103
Decreased appetiteMetabolism and nutrition disorders0/61/30/32/30/30/51/43/82/71/42/51/140/73/1410/576/344/151/137/246/271/83/1923/103
PruritusSkin and subcutaneous tissue disorders1/60/30/30/32/30/50/41/80/71/40/50/140/70/143/571/340/150/131/242/270/81/199/103
Lipase increasedInvestigations0/60/30/30/32/30/50/40/80/70/40/50/140/70/140/570/340/150/130/240/270/80/190/103
Platelet count increasedInvestigations0/60/30/30/32/30/50/40/80/70/40/50/140/70/140/570/340/150/130/240/270/80/190/103
AnaemiaBlood and lymphatic system disorders2/60/30/31/31/31/52/44/81/71/40/52/143/73/1410/574/342/153/134/245/271/82/1917/103

Baseline characteristics

Analysis was performed on all treated population.

Age, Categorical
Age, Categorical(Participants)Phase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 1Phase 1: Dose Expansion: Sub-cohort 2Phase 2Total
<=18 years000000000000000000000000
Between 18 and 65 years42222316533124114527510211818680290
>=65 years2111123221223312710339122396
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 1Phase 1: Dose Expansion: Sub-cohort 2Phase 2Total
Female412204145208613401249141614758226
Male22113134225611172211410115145160
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 1Phase 1: Dose Expansion: Sub-cohort 2Phase 2Total
Hispanic or Latino000000000000012000011229
Not Hispanic or Latino623222333237664119713162318589281
Unknown or Not Reported0101131542271714158083011296
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1: Dose Escalation: QOD Dosing: 8 mgPhase 1: Dose Escalation: QOD Dosing: 16 mgPhase 1: Dose Escalation: QOD Dosing: 24 mgPhase 1: Dose Escalation: QOD Dosing: 36 mgPhase 1: Dose Escalation: QOD Dosing: 56 mgPhase 1: Dose Escalation: QOD Dosing: 80 mgPhase 1: Dose Escalation: QOD Dosing: 120 mgPhase 1: Dose Escalation: QOD Dosing: 160 mgPhase 1: Dose Escalation: QOD Dosing: 200 mgPhase 1: Dose Escalation: QD Dosing: 4 mgPhase 1: Dose Escalation: QD Dosing: 8 mgPhase 1: Dose Escalation: QD Dosing: 16 mgPhase 1: Dose Escalation: QD Dosing: 20 mgPhase 1: Dose Escalation: QD Dosing: 24 mgPhase 1: Dose Expansion Cohort 1Phase 1: Dose Expansion: Cohort 2Phase 1: Dose Expansion: Cohort 3Phase 1: Dose Expansion: Cohort 4Phase 1: Dose Expansion: Cohort 5Phase 1: Dose Expansion: Cohort 6Phase 1: Dose Expansion: Sub-cohort 1Phase 1: Dose Expansion: Sub-cohort 2Phase 2Total
Asian/Oriental00000000000012620832103055
White/Caucasian63332135534768371772152216751233
Black or African-American0000010000100010020110815
Native Hawaiian or Other Pacific Islander000000000000000001000012
Missing/Unknown0000131321070413158062111381
08

Study locations

58 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • Mayo Clinic (AZ)
    Scottsdale, Arizona 85259, United States
  • The University of Arizona Cancer Center - North Campus
    Tucson, Arizona 85719, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center. Mission Bay
    San Francisco, California 94158, United States
  • Cancer Treatment Centers of America
    Newnan, Georgia 30265, United States
  • Cancer Treatment Centers of America Zion, IL
    Zion, Illinois 60099, United States
  • The University of Kansas Cancer Center
    Fairway, Kansas 66205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institution
    Boston, Massachusetts 02215, United States
  • Wayne State Universtity (Karmanos Cancer Institute)
    Detroit, Michigan 48201, United States
  • Mayo Clinic (MN)
    Rochester, Minnesota 55905, United States
  • New Mexico Cancer Care Alliancer
    Albuquerque, New Mexico 87106, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Sidney Kimmel Cancer Center at Jefferson
    Philadelphia, Pennsylvania 19107, United States
  • University of Pittsburgh Medical Center Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Greenville Health System ITOR,Clinical Research Unit
    Greenville, South Carolina 29605, United States
  • Spartanburg Medical Center
    Spartanburg, South Carolina 29303, United States
  • Mary Crowley Cancer Research - Medical City
    Dallas, Texas 75230, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Utah, Huntsman Cancer Hospital
    Salt Lake City, Utah 84112, United States
  • University of Virginia Cancer Center
    Charlottesville, Virginia 22903, United States
  • Virginia Mason Cancer Center
    Seattle, Washington 98101, United States
  • University of Wisconsin Clinical Science Center
    Madison, Wisconsin 53792, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Royal Melbourne Hospital
    Melbourne, Australia
  • Sunnybrook Research Institue
    Toronto, M4N3M5, Canada
  • Centre Léon Bérard Bât
    Lyon, Cedex 69373, France
  • Institut Bergonie
    Bordeaux, 33076, France
  • Hospices Civils de Lyon
    Bron, 69677, France
  • Pitié-Salpêtrière Hospital
    Paris, 75013, France
  • Rennes, Centre Eugène Marquis
    Rennes cedex, 35042, France
  • Institute Goustave-Roussy-DITEP
    Villejuif, 94805, France
  • University Hospital Essen, West German Cancer Center, Department of Medical Oncology
    Essen, 45147, Germany
  • The Chinese University of Hong Kong
    Sha Tin, Hong Kong
  • Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
    Milano, 20133, Italy
  • UOC Oncologia Medica 1 I"V - Istituto Oncologico Veneto - IRCCS
    Padova, 35128, Italy
  • Hokkaido University Hospital
    Hokkaido, 060-8648, Japan
  • Kyoto University Hospital, Department of Clinical Pharmacology and Therapeutics
    Kyoto, 606-8507, Japan
  • Tohoku University Hospital
    Miyagi, 980-8574, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • Yonsei University, Severance Hospital (Seoul)
    Seoul, 03722, Korea, Republic of
  • ASAN Medical Center (Seoul)
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center (Seoul)
    Seoul, 06351, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • University Hospital Jenna
    Jenna, 07740, Netherlands
  • Val D'Hebron University Hospital
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial de Barcelona,
    Barcelona, 08036, Spain
  • University Hospital Ramón y Cajal
    Madrid, 28034, Spain
  • Centro Integral Oncológico Clara Campal - Hospital Universitario Madrid Sanchinarro
    Madrid, Spain
  • Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • National Taiwan University Hospital
    Taipei, 10048, Taiwan
  • Guy's and St Thomas' NHS Foundation Trust
    London, SE1 9RT, United Kingdom
  • Sarah Cannon Research Institute
    London, W1G 6AD, United Kingdom
  • University College London Hospital
    London, W1T 7HA, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Bahleda R, Meric-Bernstam F, Goyal L, Tran B, He Y, Yamamiya I, Benhadji KA, Matos I, Arkenau HT. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. Ann Oncol. 2020 Oct;31(10):1405-1412. doi: 10.1016/j.annonc.2020.06.018. Epub 2020 Jul 2. PubMed 32622884 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Oct 2020, 74 months.

Results were first posted in Mar 2024, 3 years 5 months after primary completion. A results delay was requested in Sep 2021.

Of 40 phase 1/2 interventional studies under Cholangiocarcinoma, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 77. This study's 74 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2014
First posted
Feb 3, 2014
StartActual
Jul 21, 2014
Primary completionActual
Oct 1, 2020
CompletionActual
Oct 22, 2024
Results delay requested
Sep 28, 2021
Results first posted
Mar 20, 2024
Last update
Mar 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02052778
Responsible party
Sponsor
First posted
Feb 3, 2014
Start date
Jul 21, 2014
Primary completion
Oct 1, 2020
Completion
Oct 22, 2024
Results posted
Mar 20, 2024
Last update
Mar 27, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Futibatinib

Start the discussion